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Lichen Sclerosus (LS) is a chronic inflammatory dermatosis predominantly 
affecting the genitals. It can affect men, women and children. LS affecting 
female genitalia typically presents with itchy patches that impact on physical and 
psychosocial-sexual functioning1,2. Symptoms in men include difficulty urinating 
due to urethral narrowing, difficulty in foreskin retraction due to scarring, and 
dyspareunia. Complications include loss of anatomy and malignant 
transformation.  
Clinical trials are vital for evidence-based practice by providing current 
supportive evidence to inform clinical decision-making. When results of multiple 
clinical studies are pooled, a stronger evidence base is obtained than with a 
single study. However, there is inconsistency in outcomes measured in trials of 
vulval skin conditions; one systematic review found 28 vulval randomised 
controlled trials, measuring 25 outcomes using 49 different scales3. The 
heterogeneity of these outcomes/scales means they cannot be effectively 
compared or combined in meta-analyses, which is a source of research 
wastage4. 
Minimising differences in outcomes collected during trials by developing and 
using Core Outcome Sets can reduce this research ‘waste’. A Core Outcome Set 
is an agreed standardised minimum collection of outcomes that should be 
measured and reported across all clinical trials of a specific condition5.  
The aim of this study was to inform development of a Core Outcome Set for 
genital LS by establishing outcome domains of importance to patients and 
healthcare professionals.  
An online survey was disseminated to international stakeholders from 
September-October 2017 during a James Lind Alliance LS Priority Setting 
Partnership6. As this was patient and public involvement into research, ethical 
approval was not required. 
Anonymised free-text responses about ‘important symptoms or aspects of LS’ 
were collected. Data were analysed using NVivo12 software through an iterative 
sequence of qualitative analyses7. First, keywords were identified using word 
frequency counts. They were subsequently analysed in the wider context of the 
data in a ‘keyword-in-context’ analysis. This informed a thematic analysis, where 
each response was summarised/characterised using a ‘code’ (a simple label of 
content). Similar ‘codes’ were grouped within broader ‘themes’, with review of 
themes (and data captured therein) informing the generation of outcome 
domains.  
The survey was completed by 653 respondents submitting 1953 responses in 
total. 404 participants were patients/carers (92% female, 5% male) of whom 
5% were children/representatives of children. 222 participants were healthcare 
   
 
professionals (64 gynaecologists, 58 dermatologists, 35 sexual health 
physicians) and 27 ‘other’.  
Word counts identified that itch was the most commonly used ‘keyword’ (used 
395 times); contextual review identified variation in how ‘keywords’ were used 
(e.g. ‘presence of itch’ or ‘itch ceasing’). Consistent use of keywords informed 
the creation of 37 distinct ‘codes’, each code capturing a commonly reported 
experience/opinion. Codes were organised within 6 broader ‘themes’, which drew 
together closely related or connected codes (Table 1).  
Each theme points to an outcome domain of importance for LS, the thematic 
analysis therein provides insight about how to potentially operationalise that 
domain. 
Symptoms of LS, such as itching and pain, and their persistent nature cause 
significant discomfort and psychological distress (Symptoms). As such LS 
impacts on daily activities and normal functioning (Quality of Life). People with 
LS reported problems with dyspareunia, physical inability to engage in 
intercourse due to narrowing of the vaginal opening, and lack of sexual drive 
from loss of sensation. They referred to the emotional impact on relationships as 
well as their own psychosocial-sexual wellbeing (Sexual Dysfunction). Responses 
placed greater significance on the changes related to anatomical structure (229 
responses) than on variations in cosmetic appearance (70 responses) 
(Appearance).  
Many participants described fear of potential progression to malignancy and 
irreversible stenosis (Progression of the Condition). The importance of better 
awareness of LS among the general public and doctors was highlighted to aid 
earlier diagnosis and prevention of scarring. Many patients called for treatment 
that quickly resolves symptoms, reduces flare ups and is easier to use than the 
standard first-line therapy of topical steroids (Management of Condition). 
The six key themes/domains identified above will inform the first stage of 
development for a LS Core Outcome Set through the CORALS (Core Outcomes 
for ReseArch in LS) initiative8. The first stage will obtain international consensus 
on core outcome domains via an electronic-Delphi exercise. Subsequent work to 
identify appropriate outcome measurement instruments will then be needed to 
use in the final Core Outcome Set.  
Although CORALS is intended for use in randomised trials, we believe 
understanding these outcomes of importance is valuable for managing LS in the 
outpatient clinic. Ensuring that these issues are addressed during the 





















Theme/Domain Codes Example of data 
Quality of Life Impact on daily activities/ 
normal function 
“It takes a lot of everyday life…when you have to pee, you want to 
have sex, go swimming, go cycling, etc… I miss being 
spontaneous.” 
Psychological distress  “The psychological impact it has on your relationship to your 
partner” 
Sexual dysfunction Physically unable to have sex “Being able to have a normal sex life with vaginal intercourse 
(without risk of damages or pain from scratches, skin growing 
together, thin skin and other anatomical changes)” 
Dyspareunia “Able to have intercourse without the pain during and after” 
Emotional impact on 
relationships 
“Fusing, anything to stop the fusing, my partner asked why I had 
been circumcised, I'm white British female, I haven't been 
circumcised.” 
Symptoms Itching  “Flare ups of agonizing unceasing itching” 
Pain “Cracking of the skin in the vulva area, which is rather painful” 
Appearance Anatomical Change “Architecture.  I no longer have external labia, neither a noticeable 
clitoris and my vulva looks like a pair of white bicycle inner 
tubes…I very much miss feeling like a complete woman” 
Cosmetic Appearance “Scarring / ugly red patches on the genitals” 
Progression of the 
condition 
Cancer risk “Anxiety about the possible development of cancer.”  
Management of the 
condition 
Better awareness “The tendency for GPs and other practitioners to wrongly diagnose 
LS…and dismiss women presenting with repeated problems” 
Earlier diagnosis “Develop an easier way to diagnose the disease so more women 
will be able to be tested early enough.” 
Better treatment “Clearer and consistent guidance on treatment...what works best, 
when, how and how much/frequently” 
Table 1 Summary of the thematic analysis showing 6 key themes identified and the codes and 
examples of raw data that contributed to these. 
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